The patient can consult the possibility of cancer
chemoprevetion in the case of expose to high-risk
danger carcinoma
chemoprevetion in the case of expose to high-risk
danger carcinoma
The patient can consult the possibility of cancer chemoprevention
in the case of expose to high-risk danger carcinoma. Chemoprevention
of cancer is promising and hopeful branch of oncology. There are
several clinical trials, which confirm usefulness of this new approach
to oncological medicine. Although we are at the very beginning on this
field, we can use some knowledge in the clinical practise..
Several examples:
The present randomised trial for prevention of women with high risk
of breast carcinoma between Tamoxifen and Raloxifen (Evista) is not
finished. Tamoxifen is in use for women with high score of risk of
breast carcinoma and is in clinical use. Raloxifen is les carcinogen
for uterus and is in use for treatment of osteoporosis, but shows 78%
lowering of breast carcinoma for women using Raloxifen.
Sulindac sulphite and Sulindac sulphate is preventive agent for colon
carcinoma, especially for hereditary polyposis. The patients with
rheumatoid arthritis using antiflogistic agents has lower incidence
of colon cancer.
A clinical trial in Li-xian showed statistically significant influence
of some antioxidants and some trace elements for patients with
dysplastic changes. The field is too wide to describe all. The aim
is to normalize apoptosis during cancer development. (Apoptosis
is guided cell deaths. Proper healthy non-cancer cells committed
suicide due to central order - like in Socrates death!) The same
and laboratory results with genetically healthy material achieved
apoptosis normalisation.
For example:
melanoblastic malignant cells become melanocytic back again.
